retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Medscape | The investigational triple
Pay in 4 interest-free payments of $6.54 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7










00188-2/asset/9ea5f54d-addc-413f-a5f5-068aaced3d20/main.assets/gr1.jpg)















